Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies

BACKGROUND. Brentuximab vedotin is an antibody-drug conjugate designed to selectively deliver monomethyl auristatin E, a microtubule-disrupting agent, to CD30-expressing cells. Brentuximab vedotin induces durable objective responses in patients with relapsed or refractory Hodgkin lymphoma (HL) after...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Forero-Torres, Andres, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L., Rosenblatt, Joseph D., Kennedy, Dana A., Younes, Anas
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Lymphoma
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425525/
https://ncbi.nlm.nih.gov/pubmed/22855426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0133
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky